Skip to content

Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants

Tissue Procurement and Outcome Collection for Radiotherapy Treated Patients and Healthy Participants

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00992303
Enrollment
10000
Registered
2009-10-09
Start date
2009-09-01
Completion date
2029-12-01
Last updated
2026-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Keywords

unspecified adult solid tumor, protocol specific

Brief summary

RATIONALE: Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting tissue samples from patients with cancer undergoing radiation therapy. Healthy participants will also be allowed on the trial so their samples can be used in comparison to patients with malignancy

Detailed description

OBJECTIVES: Primary * To maintain and create a University of Texas Southwestern Medical Center (UTSW) Radiation Oncology Tissue Resource and Registry/Database that will be used to explore genetic variations contributing to clinical outcomes through tissue analysis and outcome correlation. Tissue will be stored by the UTSTR and the database managed by Radiation Oncology. Secondary * To document disease outcome (local recurrence, distant metastasis, overall survival) by treatment regimen and disease site. * To document toxicity by treatment regimen and disease site. * To establish a prospective registry/database consisting of patient demographics and outcomes to be used for future research. OUTLINE: Tissue, including surgical waste, venous blood/serum, urine, bone marrow, and other body fluids, may be collected (at planned surgery and routine medical visits) and preserved for future research. Demographic and disease and treatment information is obtained from patients (by interview or questionnaire), from medical records, and from national datasets. Patients may also be asked to provide additional blood samples and/or a small skin-punch biopsy sample. Patients are followed up every 6 months for the first two years following treatment and then yearly thereafter.

Interventions

OTHERbiologic sample preservation procedure
OTHERmedical chart review
OTHERquestionnaire administration

Sponsors

University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

DISEASE CHARACTERISTICS: * Pathologically-proven diagnosis of malignancy * Planning treatment with radiation therapy PATIENT CHARACTERISTICS: * Able to perform follow-up visits * Is a patient of the University of Texas Southwestern Medical Center physicians PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Participation in other clinical trials is allowed * Other prior or concurrent therapy for cancer, such as surgery and/or chemotherapy, is allowed. Criteria for eligibility: * Able to provide written informed consent * Age greater than 18 years old * Males and Females are eligible * Any ethnicity is eligible Criteria for ineligibility: -Patients not available for follow-up/future contact

Design outcomes

Primary

MeasureTime frameDescription
Maintenance a Tissue Resource and Registry/Database10 yearsMaintenance and creation of a University of Texas Southwestern Medical Center (UTSW) Radiation Oncology Tissue Resource and Registry/Database

Secondary

MeasureTime frameDescription
Local recurrence5 yearsTo document local recurrence by treatment regimen and disease site.
Distant metastasis5 yearsTo document distant metastasis by treatment regimen and disease site.
Overall survival5 yearsTo document overall survival by treatment regimen and disease site.
Toxicity by treatment regimen1 yearTo document toxicity by treatment regimen and disease site.
Establishment of a prospective registry/database10 yearsTo establish a prospective registry/database consisting of patient demographics and outcomes to be used for future research.

Countries

United States

Contacts

CONTACTSuprabha Pulipparacharuvil
suprabha.pulipparacharuvil@utsouthwestern.edu214-645-8525
PRINCIPAL_INVESTIGATORRobert Timmerman, MD

University of Texas Southwestern Medical Center - Dallas

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 18, 2026